Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to assess the need for the provision of the vaccination against Covid for (a) children and (b) adults who are suffers of Long-Covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I refer the Hon. Member to the answer I gave on 2 February 2026 to Question 108759.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of providing vaccinations against Covid-19 for children and adults who have Long Covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).
The primary aim of the national COVID-19 vaccination programme remains the prevention of serious disease, resulting in hospitalisations and deaths, arising from COVID-19. Population immunity to COVID-19 has increased due to a combination of naturally acquired immunity, following recovery from infection, and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death having reduced significantly since COVID-19 first emerged.
The focus of the programme is on vaccination of the oldest adults and individuals who are immunosuppressed. These are the two groups who continue to be at higher risk of serious disease, including mortality. In line with JCVI’s advice, in autumn 2025 a COVID-19 vaccination is being offered to:
- adults aged 75 years old and over;
- residents in care homes for older adults; and
- individuals aged six months old and over who are immunosuppressed.
On 15 December 2025, the Government accepted the JCVI’s advice for spring 2026 and in line with the advice, a COVID-19 vaccination will be offered to the same groups as in autumn 2025 and previous spring campaigns.
Long term health consequences following COVID-19, including post-COVID syndromes, such as long COVID, have been discussed at meetings of the JCVI COVID-19 sub-committee. The JCVI’s view is that it remains uncertain whether additional COVID-19 vaccine doses, for example the fourth, fifth, sixth, or seventh doses of the COVID-19 vaccine, have a significant effect on the chances of developing long COVID, how it progresses, or how it affects people. The JCVI keeps all vaccination programmes under review.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of providing limited amounts of non-mRNA COVID-19 vaccines available for patients with clinical contraindications to mRNA vaccines, including through the importation of products already authorised by trusted international regulators.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of establishing a national referral pathway or specialist hub for people who cannot receive mRNA vaccines to ensure equitable access to appropriate COVID-19 vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people are clinically unable to receive mRNA-based COVID-19 vaccines; and how this figure has been derived.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many awards had been made under the Vaccine Damage Payment Scheme for claims arising from Covid-19 vaccines as at 31 December 2025.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Data from the NHS Business Services Authority, the administrators of the Vaccine Damage Payment Scheme (VDPS), shows that as of 31 December 2025, 246 VDPS awards have been made for claims relating to COVID-19 vaccinations.
Information on COVID-19 claims to the VDPS is published on a quarterly basis by the NHS Business Service Authority. Further information is available at the following link:
https://opendata.nhsbsa.net/dataset/vdps-covid-19
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of raising the age threshold for eligibility for the Covid-19 vaccine to 75 on clinically vulnerable groups.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government’s policy on the groups eligible for vaccination programmes is based on the advice of the independent expert body, the Joint Committee on Vaccination and Immunisation (JCVI).
The JCVI and the JCVI COVID-19 sub-committee carefully considered the evidence on the risk of illness, serious disease, and death as a consequence of COVID-19, as well as modelling and cost-effectiveness analysis, during their meetings of 2024, with the minutes available on the GOV.UK website. Evidence indicated that whilst the risk from COVID-19 is now much lower for most people, adults aged 75 years old and over, residents in care homes for older adults, and those who are immunosuppressed are at highest risk of serious COVID-19 disease.
Therefore, a more targeted vaccination programme, aimed at the individuals with a higher risk of developing serious disease, and where vaccination was considered potentially cost-effective, was advised for autumn 2025.
The JCVI continues to keep the COVID-19 vaccination programme under review and, through their published list of research recommendations, has actively encouraged further research on the impact of COVID-19 in individuals with underlying medical conditions in the current epidemiological context.
Asked by: Rupert Lowe (Independent - Great Yarmouth)
Question to the Cabinet Office:
To ask the Minister for the Cabinet Office, if the Government will launch an inquiry into vaccine harms and excess deaths during Covid-19 lockdowns.
Answered by Nick Thomas-Symonds - Paymaster General and Minister for the Cabinet Office
Our thoughts are with the families of those who lost loved ones and those who continue to suffer because of the pandemic.
The UK Covid-19 Inquiry was established in 2022 under the Inquiries Act. The Government is fully committed to supporting the work of the Inquiry and to learning lessons from the Covid-19 pandemic to ensure the UK is better prepared for a future pandemic.
Module 2 of the Inquiry investigated matters including decision-making relating to lockdowns. The Inquiry published its report in November last year - the Government will consider the Inquiry’s findings and recommendations carefully before responding in full. Module 4 of the Inquiry is investigating a range of issues relating to the development of Covid-19 vaccines and the implementation of the vaccine rollout programme - the Inquiry is expected to publish its report in April 2026.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department will consider allowing families of vulnerable patients who are at highest risk, particularly those affected by transplants and kidney disease, access to NHS COVID vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The JCVI has advised that population immunity to COVID-19 has increased due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.
The JCVI has also advised that as currently available COVID-19 vaccines provide limited protection against transmission and mild or asymptomatic disease, the focus of the programme is on offering vaccination to those most likely to directly benefit from vaccination. These are the oldest adults and individuals who are immunosuppressed.
The Government has accepted the JCVI advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps the evidence under regular review.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will review the adequacy of the eligibility criteria for NHS-funded COVID-19 vaccinations for carers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
For autumn 2024, the JCVI advised that in an era of high population immunity to COVID-19 and all cases due to Omicron sub-lineages of the virus, any protection against transmission of infection from one person to another is expected to be extremely limited. These considerations informed the JCVI’s advice that unpaid carers, household contacts of the immunosuppressed, and frontline health and social care workers should no longer be offered vaccination to protect those they cared for from transmission.
In their advice covering 2025 and spring 2026, the JCVI advised that population immunity to COVID-19 has increased due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.
The focus of the JCVI-advised programme has therefore moved towards targeted vaccination of the two groups who continue to be at higher risk of serious disease, including mortality. These are the oldest adults and individuals who are immunosuppressed.
The Government has accepted the JCVI advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
The JCVI keeps all vaccination programmes under review.